Tags

Type your tag names separated by a space and hit enter

Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.
Antimicrob Agents Chemother. 1999 Jan; 43(1):163-5.AA

Abstract

The pharmacokinetics in serum and leukocyte (WBC) exposures of 1,500 mg of oral azithromycin administered as 3-day (500 mg/day, days 1 to 3) and 5-day (500 mg on day 1 and 250 mg/day on days 2 to 5) regimens were compared in 12 healthy volunteers. Serum, polymorphonuclear leukocytes, and mononuclear leukocytes were collected over a 12-day period from the start of each regimen. Results of the study indicate that the exposures of serum and both types of WBCs were similar with both regimens. Drug concentrations in day 12 WBCs were well above the MICs for all relevant community-acquired respiratory tract pathogens. Terminal half-lives in serum obtained by both regimens were essentially equal at 66 h and consistent with past reports. These results indicate that the standard 1,500-mg dose of oral azithromycin can be administered over either 5 or 3 days.

Authors+Show Affiliations

Clinical Pharmacology Research Center, Departments of Pharmacy and Medicine, and Research Institute, Bassett Healthcare, Cooperstown, New York 13326, USA. guy.amsden@bassett.orgNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9869584

Citation

Amsden, G W., et al. "Pharmacokinetics in Serum and Leukocyte Exposures of Oral Azithromycin, 1,500 Milligrams, Given Over a 3- or 5-day Period in Healthy Subjects." Antimicrobial Agents and Chemotherapy, vol. 43, no. 1, 1999, pp. 163-5.
Amsden GW, Nafziger AN, Foulds G. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob Agents Chemother. 1999;43(1):163-5.
Amsden, G. W., Nafziger, A. N., & Foulds, G. (1999). Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrobial Agents and Chemotherapy, 43(1), 163-5.
Amsden GW, Nafziger AN, Foulds G. Pharmacokinetics in Serum and Leukocyte Exposures of Oral Azithromycin, 1,500 Milligrams, Given Over a 3- or 5-day Period in Healthy Subjects. Antimicrob Agents Chemother. 1999;43(1):163-5. PubMed PMID: 9869584.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. AU - Amsden,G W, AU - Nafziger,A N, AU - Foulds,G, PY - 1998/12/31/pubmed PY - 1998/12/31/medline PY - 1998/12/31/entrez SP - 163 EP - 5 JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 43 IS - 1 N2 - The pharmacokinetics in serum and leukocyte (WBC) exposures of 1,500 mg of oral azithromycin administered as 3-day (500 mg/day, days 1 to 3) and 5-day (500 mg on day 1 and 250 mg/day on days 2 to 5) regimens were compared in 12 healthy volunteers. Serum, polymorphonuclear leukocytes, and mononuclear leukocytes were collected over a 12-day period from the start of each regimen. Results of the study indicate that the exposures of serum and both types of WBCs were similar with both regimens. Drug concentrations in day 12 WBCs were well above the MICs for all relevant community-acquired respiratory tract pathogens. Terminal half-lives in serum obtained by both regimens were essentially equal at 66 h and consistent with past reports. These results indicate that the standard 1,500-mg dose of oral azithromycin can be administered over either 5 or 3 days. SN - 0066-4804 UR - https://www.unboundmedicine.com/medline/citation/9869584/Pharmacokinetics_in_serum_and_leukocyte_exposures_of_oral_azithromycin_1500_milligrams_given_over_a_3__or_5_day_period_in_healthy_subjects_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=9869584 DB - PRIME DP - Unbound Medicine ER -